Local delivery of drug to the target organ via inhalation offers enormous benefits in the
management of many diseases. Lung cancer is the most common of all cancers and it is the leading
cause of death worldwide. Currently available treatment systems (intravenous or oral drug delivery)
are not efficient in accumulating the delivered drug into the target tumor cells and are usually associated
with various systemic and dose-related adverse effects. The pulmonary drug delivery technology
would enable preferential accumulation of drug within the cancer cell and thus be superior to intravenous
and oral delivery in reducing cancer cell proliferation and minimising the systemic adverse effects.
Site-specific drug delivery via inhalation for the treatment of lung cancer is both feasible and efficient.
The inhaled drug delivery system is non-invasive, produces high bioavailability at a low dose
and avoids first pass metabolism of the delivered drug. Various anticancer drugs including chemotherapeutics,
proteins and genes have been investigated for inhalation in lung cancers with significant outcomes.
Pulmonary delivery of drugs from dry powder inhaler (DPI) formulation is stable and has high
patient compliance. Herein, we report the potential of pulmonary drug delivery from dry powder inhaler
(DPI) formulations inhibiting lung cancer cell proliferation at very low dose with reduced unwanted
Keywords: Anticancer drugs, chemotherapeutic agents, dry powder inhaler formulations, inhalation, lung cancer, pulmonary
Rights & PermissionsPrintExport